REPLIGEN CORPORATION

(RGEN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 05/26 04:00:01 pm
160.645 USD   +4.19%
05:53pREPLIGEN : Statement of Changes in Beneficial Ownership (Form 4)
PU
05:30pINSIDER SELL : Repligen
MT
04:31pRepligen Appoints Dr. Konstantin Konstantinov to Board of Directors
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation Promotes James Bylund to the Chief Operating Officer and Principal Operating Officer

01/04/2022 | 07:01am EDT

On January 3, 2022, Repligen Corporation promoted James Bylund, the company’s current Senior Vice President, Operations and Information Technologies, to the role of Chief Operating Officer of the Company, effective January 1, 2022. In connection with this promotion, Mr. Bylund was also appointed by the Company to serve as the Company’s principal operating officer. Mr. Bylund joined the Company in March 2020 as Senior Vice President, Operations and Information Technologies, responsible for overseeing all operations and information technology functions on a global basis. Prior to joining the Company, Mr. Bylund spent ten years at Thermo Fisher Scientific in a number of roles including Vice President and General Manager of the Single Use Technologies Business Unit and Vice President of Global Operations for the Bioproduction Division.


© S&P Capital IQ 2022
All news about REPLIGEN CORPORATION
05:53pREPLIGEN : Statement of Changes in Beneficial Ownership (Form 4)
PU
05:30pINSIDER SELL : Repligen
MT
04:31pRepligen Appoints Dr. Konstantin Konstantinov to Board of Directors
AQ
05/25Repligen Corporation to Present at Upcoming Investor Conferences
AQ
04/28Craig-Hallum Adjusts Repligen's Price Target to $274 From $286, Reiterates Buy Rating
MT
04/28KeyBanc Adjusts Repligen's Price Target to $245 From $335, Keeps Overweight Rating
MT
04/27REPLIGEN CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
04/27SECTOR UPDATE : Health Care Stocks Posting Small Gains Ahead of Wednesday's Close
MT
04/27SECTOR UPDATE : Health Care
MT
04/27Repligen Reports Higher Q1 Adjusted Earnings, Revenue; Reduces 2022 Guidance -- Shares ..
MT
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2022 787 M - -
Net income 2022 139 M - -
Net cash 2022 436 M - -
P/E ratio 2022 66,8x
Yield 2022 -
Capitalization 8 823 M 8 823 M -
EV / Sales 2022 10,7x
EV / Sales 2023 9,17x
Nbr of Employees -
Free-Float 93,2%
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 159,17 $
Average target price 239,89 $
Spread / Average Target 50,7%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen T. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION-42.82%8 547
ABBOTT LABORATORIES-19.58%198 189
MEDTRONIC PLC2.02%141 586
BECTON, DICKINSON AND COMPANY2.60%71 882
HOYA CORPORATION-19.84%39 348
BAXTER INTERNATIONAL INC.-12.41%37 860